Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861310 | 0.91 | SLC6A5 (0.46) | SLC6A5CASP2NAAAGNAI3GNAO1 | |
| SCHEMBL19861156 | 0.88 | CASP2 (0.42) | SLC6A5CASP2NAAARRM1EPHX1 | |
| SCHEMBL21025679 | 0.78 | MEN1 (0.38) | CASP2EPHX1FAAH | |
| SCHEMBL20076165 | 0.77 | CASP2 (0.43) | SLC6A5CASP2NAAARRM1EPHX1 | |
| SCHEMBL23015887 | 0.76 | FAAH (0.39) | CASP2NAAAEPHX1FAAH | |
| SCHEMBL7885117 | 0.75 | EPHX1 (0.50) | SLC6A5CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL20417363 | 0.74 | CASP2 (0.56) | CASP2NAAAEPHX1FAAH | |
| SCHEMBL115809 | 0.74 | SLC6A5 (0.73) | SLC6A5CASP2NAAAFAAH | |
| SCHEMBL24682149 | 0.74 | SLC6A5 (0.73) | SLC6A5CASP2NAAAFAAH | |
| SCHEMBL25007851 | 0.74 | CES2 (0.40) | CASP2EPHX1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | SLC6A5 1416/4885CASP2 1407/4885NAAA 4715/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | SLC6A5 1543/4885CASP2 1390/4885NAAA 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.